The distribution and pricing of prescription drugs

International Journal of the Economics of Business

Volumn 4, Issue 3, 1997, Pages 287-300

  Elzinga, Kenneth G ^a   Mills, David E ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

JEL classifications: D40, L40, L65; Pharmaceutical industry; Price discrimination; Prescription drug pricing; Managed care

Indexed keywords

EID: 0001038465     PISSN: 13571516     EISSN: 14661829     Source Type: Journal    
DOI: 10.1080/758523211     Document Type: Article

References (10)

1. Blissenbach, H.F. 1993. “Pharmaceutical Services in Managed Care”. In The Managed Health Care Handbook, 2nd, Edited by: Kongstvedt, P.R., 142–160. Gaithersburg: Aspen.
2. Boston Consulting Group. 1993. The Changing Environment for U.S. Pharmaceuticals, Boston: Boston Consulting Group.
3. Comanor, W.S, and Schweitzer, S.O. 1995. “Pharmaceuticals”. In The Structure of American Industry, 9 Edited by: Adams, W., and Brock, J., 177–196. Englewood Cliffs: Prentice-Hall.
4. Grabowski, H.G, and Vernon, J.M., 1986. “Longer Patents for Lower Invitation Barriers: The 1984 Drug Act”. American Economic Review, 76: 195–198.
5. In Re: Brand Name Prescription Drugs Antitrust Litigation, MDL No. 997, U.S.D.C. for N.D. of IL, Eastern Div
6. Kongstvedt, P.R, ed. 1993. The Managed Health Care Handbook, 2, Gaithersburg: Aspen.
7. Martin, S., 1994. Industrial Economics, 2, New york: Macmillian.
8. Mathewson, F, and Winter, R.A., 1996. “Buyer Groups”. International Journal of Industrial Organization, 15: 137–164.
9. Pindyck, R.S, and Rubinfeld, D. 1995. Microeconomics, 3, Englewood Cliffs: Prentice-Hall.
10. Scherer, F.M. 1997. “How U.S. Antitrust Can Go Astray: The Brand Name Prescription Drug Litigation”. International Journal of the Economics of Business, 4 (3): 239–256.